Showing 16,641 - 16,660 results of 106,247 for search '(( 5 ((nn decrease) OR (a decrease)) ) OR ( e ((non decrease) OR (point decrease)) ))', query time: 1.84s Refine Results
  1. 16641
  2. 16642

    Table 5_Interaction with IGF1 overrides ANXA2-mediated anti-inflammatory functions of IGFBP5 in vivo.docx by Yan Fan (575147)

    Published 2025
    “…Background<p>IGFBP5 is a differentially expressed gene (DEG) between M1 and M2 macrophages. …”
  3. 16643

    Image_5_Autophagy Induced Accumulation of Lipids in pgrl1 and pgr5 of Chlamydomonas reinhardtii Under High Light.TIF by Nisha Chouhan (11994860)

    Published 2022
    “…<p>Chlamydomonas (C.) reinhardtii is a potential microalga for lipid production. Autophagy-triggered lipid metabolism in microalgae has not being studied so far from a mutant of proton gradient regulation 1 like (PGRL1) and proton gradient regulation 5 (PGR5). …”
  4. 16644

    BMD analysis of serum free T4 (A), serum free T3 (B) and serum TSH (C) in males (triangles) and females (circles). by Matti Viluksela (321291)

    Published 2014
    “…Small symbols indicate individual samples, large symbols the group mean; the vertical dotted line indicates the dose (CED) with 5% decrease or increase (CES -0.05) compared to background (a parameter). …”
  5. 16645

    Table_1_Investigating the Added Value of the EQ-5D-5L With Two Bolt-On Items in Patients With Hemophilia.DOCX by Richard Huan Xu (7901480)

    Published 2021
    “…Spearman's rank correlation (rho) was used to assess the associations of the EQ-5D-5L and two bolt-on items with the Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL) and SF-12. …”
  6. 16646
  7. 16647

    Comparison of the outcome of non-Markovian SIR processes for different values of the parameter <i>ϵ</i>. by Christian L. Vestergaard (820413)

    Published 2015
    “…</mo><mn>2</mn></mrow></msubsup></mrow></math>; nodes’ recovery times followed <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1004579#pcbi.1004579.e103" target="_blank">Eq (23)</a> with <i>γ</i> = 1.5 and <i>μ</i><sub>0</sub> = 10<sup>−4</sup> Hz; the length of a time-step was Δ<i>t</i> = 1 s and the infection rate β = 100μ<sub>0</sub> = 10<sup>−2</sup> Hz.…”
  8. 16648

    Design of a RSSCA system for agriculture. by Ngoc-Hai Vu (22290844)

    Published 2025
    “…<div><p>Agricultural land is increasingly under pressure from expanding solar energy infrastructure, leading to a growing conflict between food and energy production. …”
  9. 16649
  10. 16650

    Ybx1 regulation of its target mRNAs is m<sup>5</sup>C-depdendent (Related to Fig 5). by Jian Zhang (1682)

    Published 2025
    “…<p><b>(A)</b> RT-qPCR confirmed the decreased expression levels of Ybx1 target mRNAs in neural stem cells with Ybx1 knockdown using siRNA. …”
  11. 16651

    Image_2_Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.TIF by Jian Wu (41301)

    Published 2021
    “…As a stable indicator, the changes in IL-6 levels could indicate the inflammatory conditions during a viral infection. …”
  12. 16652

    Image_6_Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.TIF by Jian Wu (41301)

    Published 2021
    “…As a stable indicator, the changes in IL-6 levels could indicate the inflammatory conditions during a viral infection. …”
  13. 16653

    Image_1_Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.TIF by Jian Wu (41301)

    Published 2021
    “…As a stable indicator, the changes in IL-6 levels could indicate the inflammatory conditions during a viral infection. …”
  14. 16654

    Image_3_Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.TIF by Jian Wu (41301)

    Published 2021
    “…As a stable indicator, the changes in IL-6 levels could indicate the inflammatory conditions during a viral infection. …”
  15. 16655

    Image_4_Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.TIFF by Jian Wu (41301)

    Published 2021
    “…As a stable indicator, the changes in IL-6 levels could indicate the inflammatory conditions during a viral infection. …”
  16. 16656

    Five years comparation of efficacy and safety after ICL-V4c implantation for high and super high myopia correction by Qi Wan (271320)

    Published 2024
    “…No significant difference of ECD was found in the high (2823.45 ± 274.75 cells/mm<sup>2</sup>) and super-high myopia (2856.71 ± 323.53cells/mm<sup>2</sup>) at the visit of 5 years. Compared to baseline, we observed a significant increase in IOP at the 1-week follow-up, which decreased significantly at the one-month visit. …”
  17. 16657

    List of Included studies. by Zahra Tajik (20752452)

    Published 2025
    “…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  18. 16658

    The search strategy in three databases. by Zahra Tajik (20752452)

    Published 2025
    “…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  19. 16659

    NIH score. by Zahra Tajik (20752452)

    Published 2025
    “…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  20. 16660

    List of excluded studies. by Zahra Tajik (20752452)

    Published 2025
    “…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”